Mechanistically, NKILA is mainly upregulated by NF-κB activation; in turn, NKILA forms a negative feedback loop to suppress NF-κB by binding the cytoplasmic NF-κB/IκB compound and forming another stable NF-κB:IκB:NKILA complex, and suppressing the phosphorylated level of IκB, thereby preventing the nuclear translocation of NF-κB and exerting its anti-metastasis impact on breast cancer. Here, NKILA is linked to breast cancer.